Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool below to find open protocols for your type of cancer. To learn more about eligibility and participation call 877-789-6100.

Search by conditions: 

Click a protocol # to view extended details on a particular clinical trial.

Protocol #DescriptionPhase
13-587A Dose-Escalation, Phase I/II, Open-Label, Three-Part Study of the MEK Inhibitor, trametinib, Combined with the CDK4/6 Inhibitor, palbociclib, To Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity in Subjects with Solid Tumors  (View details on clinicaltrial.gov)Phase II
14-031A Multicenter Phase 1A/1B Ascending Dose Study of DCC-2701 to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients with Metastatic Melanoma  (View details on clinicaltrial.gov)Phase I
13-523A Phase 1 Study of LY3009120 in Patients with Advanced or Metastatic Cancer  (View details on clinicaltrial.gov)Phase I
14-332A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined with Trametinib and Dabrafenib or Trametinib in Adult Subjects with Metastatic Cutaneous Melanoma  (View details on clinicaltrial.gov)Phase II
12-487A Phase I Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (BMS-986015) Administered in Combination with Anti-PD-1 (BMS-936558) in Advanced Refractory Solid Tumors  (View details on clinicaltrial.gov)Phase I
13-606A Phase I Open-label Study of Safety and Tolerability of MEDI4736 in Subjects with Metastatic or Unresectable Melanoma in Combination with Dabrafenib and Trametinib or with Trametinib Alone  (View details on clinicaltrial.gov)Phase I
09-307A Phase I Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients with Advanced, Incurable, Solid Tumor or Hematologic Malignancies in which the Target Kinases Are Linked to Disease Pathophysiology  (View details on clinicaltrial.gov)Phase I
12-376A Phase Ib, Open-Label Study of the Safety and Pharmacology of MPDL3280A Administered in Combination with Vemurafenib in Patients with Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma  (View details on clinicaltrial.gov)Phase I
10-137A Phase II Study of the HSP Inhibitor STA-9090 in Metastatic Ocular Melanoma  (View details on clinicaltrial.gov)Phase II
14-062A Phase II, Open-Label, Multicentre Study of Dabrafenib Plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain  (View details on clinicaltrial.gov)Phase II
13-508A Phase III randomized, 3-arm, open label, multicenter study of LGX818 plus MEK162 and LGX818 monotherapy compared with vemurafenib in patients with unresectable or metastatic BRAF V600 mutant melanoma  (View details on clinicaltrial.gov)Phase III
13-138A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma  (View details on clinicaltrial.gov)Phase III
12-423An Exploratory Study of the Biologic Effects of BMS-936558 (Anti-PD-1 Monoclonal Antibody) Treatment in Subjects with Advanced Melanoma (Unresectable or Metastatic)  (View details on clinicaltrial.gov)Phase I
13-272Analysis of the kinetics and effects of vemurafenib on intratumoral and host immunity in patients with advanced BRAFV600 mutant melanoma: implications for combination with immunotherapy  (View details on clinicaltrial.gov)N/A
12-343COMBAT 1: A Phase II Trial of Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma  (View details on clinicaltrial.gov)Phase II
09-194E2607 - A Phase II Trial of Dasatinib in KIT-Positive Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanomas  (View details on clinicaltrial.gov)Phase II
13-339Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination with Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma  (View details on clinicaltrial.gov)Phase I
11-385Phase I Study of Single Agent MK-3475 in Patients with Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma  (View details on clinicaltrial.gov)Phase I
13-424Phase I/II study of Dabrafenib, Trametinib, and Navitoclax in BRAF mutant melanoma and other solid tumors  (View details on clinicaltrial.gov)Phase II
19 clinical trials listed.

Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.